Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.42 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31354658 | 1.00 | MAPK1 (0.65) | MAPK1KDM4EL3MBTL1LCKGABRA1 | |
| SCHEMBL435154 | 0.80 | GABRA2 (0.57) | MAPK1KDM4EGABRA1GABRG2GABRB3 | |
| SCHEMBL31463327 | 0.78 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1LCKGABRA1 | |
| SCHEMBL69747 | 0.78 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1ALDH1A1MAPT | |
| SCHEMBL29508473 | 0.78 | MAPK1 (1.00) | MAPK1KDM4EL3MBTL1ALDH1A1MAPT | |
| SCHEMBL31463324 | 0.78 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1LCKGABRA1 | |
| SCHEMBL164488 | 0.78 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1LCKGABRA1 | |
| SCHEMBL82621 | 0.78 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1LCKGABRA1 | |
| SCHEMBL29565067 | 0.78 | MAPK1 (0.67) | MAPK1KDM4EL3MBTL1LCKGABRA1 | |
| SCHEMBL13075575 | 0.78 | MAPK1 (0.61) | MAPK1KDM4EL3MBTL1LCKGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745134-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12351570-B2 | Disubstituted alkyne derivatives | MERCK PATENT GMBH (DE) | 2025-07-08 | — | — | US | disclosed |
| CN-119930509-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-114929672-B | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| EP-4392415-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2024-07-03 | — | — | EP | disclosed |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2024-05-14 | — | — | US | disclosed |
| CN-117980297-A | Substituted aminopyridine compounds as EGFR inhibitors | 柳韩洋行 | 2024-05-03 | — | — | CN | disclosed |
| WO-2024049977-A1 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | CHINOOK THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023109521-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 凯复(苏州)生物医药有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-6649612-B1 | Combating skin ageing and keratinization | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-18 | — | — | US | disclosed |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | GALDERMA RESEARCH & DEVELOPMENT | 2003-05-29 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| US-6441010-B2 | USEFUL AS COSMETIC FOR HAIR AND BODY HYGIENE, AND FOR TREATMENT OF DERMATOLOGICAL COMPLAINTS, WITH AN INFLAMMATORY AND/OR IMMUNOALLERGIC COMPONENT OF RHEUMATIC OR RESPIRATORY TYPE, CARDIVASCULAR AND OPTHALMOGICAL DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-08-27 | — | — | US | disclosed |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | GALDERAMA RESEARCH & DEVELOPMENT. | 2001-12-27 | — | — | US | disclosed |
| US-6316009-B1 | FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-11-13 | — | — | US | disclosed |
| US-6201019-B1 | ANTIINFLAMMATORY AGENTS; SIDE EFFECT REDUCTION | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-03-13 | — | — | US | disclosed |
| CN-1236354-A | Aryl-or heteroaryl-substituted biphenyl derivatives and pharmaceutical and cosmetic compositions containing them | GALDERMA RES & DEV (FR) | 1999-11-24 | — | — | CN | disclosed |
| CN-1236359-A | Bi-aromatic compounds bond by a heteroethynytene radical and pharmaceutical and comsmetic compositions containing same | GALDERMA RES & DEV (FR) | 1999-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | MAPK1 2021/4885KDM4E 3975/4885L3MBTL1 1489/4885 |
| US-12351570-B2 | Disubstituted alkyne derivatives | BRCA1, MYC, PCNA | MAPK1 1307/4885KDM4E 2366/4885L3MBTL1 625/4885 |
| US-20010056105-A1 | Bi-aromatic compounds linked via a heteroethynylene radical, and pharmaceutical and cosmetic compositions containing them | TYR, KRT18, SCO2 | MAPK1 3034/4885KDM4E 775/4885L3MBTL1 4515/4885 |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | MAPK1 515/4885KDM4E 2715/4885L3MBTL1 3384/4885 |
| US-12612368-B2 | Cancer treatments targeting cancer stem cells | MALT1, BCOR, MCL1 | MAPK1 2918/4885KDM4E 2964/4885L3MBTL1 134/4885 |
| US-20030100583-A1 | Bi-aromatic compounds linked via a heteroethylene radical, and pharmaceutical and cosmetic compositions using them | TYR, AHR, CYP2C19 | MAPK1 4372/4885KDM4E 536/4885L3MBTL1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.